Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

Clinical trial NCT00655837 · COMPLETED

Trial details

NCT number: NCT00655837
Sponsor: Seagen Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin

Start date: 2008-04-01
Primary completion: 2010-02-01
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.